Pharmacists are increasingly using AI in practice — for medicines queries, counselling preparation, clinical summaries, patient-facing explanations, revalidation reflections, and exam revision. The tools are genuinely useful when used within professional boundaries. But the line between AI support and AI substitution is one that every pharmacist must understand clearly, because the GPhC has made its expectations explicit.
The GPhC's revalidation guidance states that AI should not substitute professional judgement and that pharmacy professionals remain accountable for confirming the accuracy of AI-generated information and references. This is not a prohibition. It is a framework for responsible use — and it applies to every pharmacist using any AI tool in any clinical, educational, or professional context.
Where AI Helps in Practice
Medicines queries. The questions that arise dozens of times per day in dispensary and clinical practice: "Can this be used in pregnancy?" "What monitoring is required for this drug?" "What are the clinically important adverse effects?" "Is there a significant interaction with the patient's other medications?" AI can retrieve and organise relevant information faster than manually navigating the eMC, BNF, or NICE — but the pharmacist must verify the answer against the patient's specific clinical context before acting. The AI retrieves. The pharmacist applies patient-specific judgement.
Counselling preparation. Generating structured counselling points from SmPC data — key administration instructions, common versus serious side effects, interaction warnings, missed-dose advice, monitoring requirements, and when to seek help. AI can produce a comprehensive counselling framework in seconds; the pharmacist then adapts it for the individual patient's health literacy, concurrent medications, and specific concerns. A counselling framework generated for "amlodipine" needs patient-specific adaptation for a 78-year-old with peripheral oedema versus a 45-year-old with no comorbidities.
Clinical summaries and documentation. Medication review summaries, discharge reconciliation notes, and prescribing rationale documentation. In busy dispensaries and during Pharmacy First consultations, AI can structure the clinical summary faster than manual writing — but the pharmacist verifies accuracy, checks drug names and doses, and takes professional responsibility for every element of the final document.
Revalidation and CPD. The GPhC permits AI use for grammar, reviewing records, reflection, and references — acknowledging that revalidation documentation is time-consuming and that AI can reduce the administrative friction. The boundary is clear: AI can help structure genuine reflections from real learning experiences. It must not fabricate submissions, generate full records from scratch, or create false CPD entries. The GPhC explicitly states that using AI to create full revalidation submissions or falsify information is inappropriate.
Exam revision. Generating explanations, comparison tables, worked calculation examples, and "why not the other options?" reasoning. AI can explain why an ACE inhibitor is preferred over a calcium channel blocker in a diabetic patient with proteinuria — but the CRA tests whether the trainee can select the correct answer from five plausible options under time pressure. Explanation creates comprehension. Q-bank practice creates exam performance. Both are needed.
The Professional Boundary: AI Supports, Pharmacists Decide
The GPhC has published a position statement on AI in pharmacy, including its approach to empowering pharmacists to use AI safely and effectively. The core principle is accountability: the pharmacist remains responsible for every clinical decision, every medicine supply, every counselling interaction, and every patient safety judgement — regardless of whether AI was involved.
What pharmacists should never outsource to AI: final clinical decision-making (the AI informs; the pharmacist decides), legal and professional accountability (no AI tool assumes the pharmacist's regulatory obligations under the Pharmacy Order, the Medicines Act, or the GPhC Standards), revalidation authenticity (fabricated submissions are a fitness-to-practise concern), medicine supply decisions without source-checking (every supply should be verifiable against the SmPC, BNF, or relevant guideline), and patient-specific judgement (the AI does not know the patient's full clinical context — allergies, renal function, hepatic impairment, pregnancy, concurrent medications, clinical history, and preferences).
Why Medicines Information Needs Source-Grounding
Generic chatbots can answer medicines questions — but they draw from broad training data that may include US drug information, patient forums, outdated sources, and content from healthcare systems with different licensed indications, formulations, and monitoring requirements. For pharmacists, the source matters as much as the answer.
The electronic Medicines Compendium (eMC) contains regulated and approved information on medicines available in the UK — including SmPCs, PILs, risk minimisation materials, and safety alerts. SmPCs are checked and approved by the MHRA or EMA. Information comes directly from pharmaceutical companies or via regulators. This is the authoritative source for UK medicines information.
A counselling point that cites SmPC section 4.6 is verifiable in seconds. A counselling point from a generic AI with no visible source requires independent verification of every claim — which may take longer than looking up the SmPC directly, defeating the purpose of using AI.
What "Safe Use" Means: A Practical Checklist
For every AI-assisted medicines decision, check: the source (is the answer traceable to the SmPC, BNF, or a NICE guideline?), the patient context (does the answer apply to this specific patient's age, weight, renal function, hepatic function, allergies, comorbidities, and concurrent medications?), the dose (is it within licensed parameters for the specific indication and this patient?), contraindications and interactions (has the AI flagged everything relevant — including UK-specific risk minimisation materials?), monitoring requirements (what needs to be checked and when — and is this consistent with any shared-care protocol?), and red flags (are there warning signs that require escalation to a prescriber or urgent care rather than pharmacy management?).
Where Ask iatroX and the Premium Q-Bank Fit
Ask iatroX is designed for the clinical question behind the medicine decision — medicines information powered directly via eMC/SmPC, structured for pharmacist use, with visible citations the pharmacist can verify. The iatroX premium pharmacist Q-bank converts the same clinical knowledge into GPhC CRA-style exam practice — SBAs, EMQs, and calculations mapped to the 2026 framework.
Ask iatroX helps understand the concept. The Q-bank tests whether you can apply it under exam conditions. For pharmacists, the safest use of AI is not to replace professional judgement, but to strengthen it.
Try Ask iatroX for medicines questions, and the premium pharmacist Q-bank for GPhC-style revision →